A novel treatment strategy for type 2 diabetes: Targeting glucose variability and β-cell failure.
Blood glucose control has been a main focus for the treatment of type 2 diabetes. However, poor control and side-effect still are urgent problems to be solved. According to common blood glucose variability and its extremely deleterious diabetic-related complications in clinical practice, it should be considered as a potential key target. And β-cell failure has been approved that it can be reversible for early type 2 diabetes, which suggests another promising target. In this hypothesis, we propose a novel treatment strategy against on the two targets. An intelligent double-target drug delivery system is presented and characterized by dual-responsive functional gates for glucose sensitivity used controlled-release hypoglycemic agents and a sustained-release osmotic pump loaded drugs to repair impaired β-cell into the repository, respectively. The proposition may provide a new early therapeutic strategy for type 2 diabetes in order to better hold blood glucose homeostasis.
Key Laboratory of Biorheological Science and Technology (Chongqing University), Ministry of Education, College of Bioengineering, Chongqing University, Chongqing 400030, PR China.
Jia
J
Deng
Bochu
B
Wang
Yang
Y
Cao
Liancai
L
Zhu
D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D016503:Drug Delivery Systems; D006706:Homeostasis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D050417:Insulin-Secreting Cells / Q000166:cytology*; D008954:Models, Biological; D008962:Models, Theoretical
D001786:Blood Glucose; D007004:Hypoglycemic Agents